Is Definium Therapeutics, Inc. (DFTX) Stock a Biotech Opportunity After Positive DT120 Depression Trial Data?

1 month ago 8

Laiba Immad

Wed, July 15, 2026 astatine 4:24 AM CDT 2 min read

We precocious compiled a database of the 7 Best Psychedelic Stocks to Buy According to Analysts. Definium Therapeutics, Inc. (NASDAQ:DFTX) is 1 of the best psychedelic stocks on our list.

TheFly reported connected June 30 that Canaccord reduced its terms people connected DFTX to $58 from $60 portion reaffirming a Buy standing connected the shares. The steadfast noted that the institution precocious delivered beardown Phase 3 results from the EMERGE proceedings evaluating DT120, an orally disintegrating LSD d-tartrate tablet for large depressive disorder. The affirmative objective result was good received by investors and enabled Definium to rise astir $805 cardinal successful caller capital. Canaccord updated its fiscal exemplary to bespeak the caller financing transaction and the resulting summation successful the company's outstanding stock count.

Is Definium Therapeutics, Inc. (DFTX) Stock a Biotech Opportunity After Positive DT120 Depression Trial Data?

Is Definium Therapeutics, Inc. (DFTX) Stock a Biotech Opportunity After Positive DT120 Depression Trial Data?

Photo by Florian van Duyn connected Unsplash

Separately, it was reported connected June 25 that Definium Therapeutics, Inc. announced the completion of its antecedently disclosed underwritten nationalist offering of 23,676,471 communal shares, including the afloat workout of the underwriters' enactment for further shares. The shares were sold astatine a nationalist offering terms of $34.00 per share, generating astir $805 cardinal successful gross proceeds earlier expenses. Definium plans to allocate the proceeds toward advancing its probe and improvement programs, preparing for the imaginable commercialization of DT120 ODT if approved, and supporting wide firm needs. J.P. Morgan, Jefferies, Leerink Partners, and BofA Securities served arsenic associated pb bookrunners for the offering, which closed connected June 25, 2026.

Definium Therapeutics, Inc. (NASDAQ:DFTX) is simply a clinical-stage biopharmaceutical institution processing psychedelic and psychoplastogenic therapies for encephalon wellness disorders, including anxiety, depression, and autism spectrum disorder.

While we admit the imaginable of DFTX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years 

Disclosure: None. Follow Insider Monkey connected Google News.

Read Entire Article